Chief Business Officer
CurrentActivSignal's MPAD platform (Multiplex Paired-antibody Amplified Detection assay) measures activity along multiple signaling pathways in one reaction. More than 20 signaling pathways can be monitored simultaneously in a single well by measuring 70 target proteins for modifications, cleavage and expression. The company is currently working on an NSF Phase 2.